Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Hydroqcon May 21, 2024 11:48pm
154 Views
Post# 36051260

RE:The evidence is clear

RE:The evidence is clearENEMEASSH-OLEMO just want your share.,
Otherwise, for what other purpose, would he and Rrunningbuck, Quintin, # spend all their time bashing this stock..

I think Notable is one of the most valuable poster on here.  One of a kind, and I don't read each and all of his/her cut and paste, but overall, I have a more global picture of the biotech sector since I don't have the time and the focus for all that search. I will call that COMPLEMENTARY good information.

I am just keepinging my share till the end. The fundamental is just too strong and very well documented. The next few months are meant to be very exciting in my view.
2, maybe 3 phase III trial coming. With partners or with a buy out.

Those who are convinced that ONC wil not get to the finish line, should sell at 1,50 so you won't lose everything. Until you find out PELAREOREP is part of the new standard of care for many cancer.

Let's enjoy the rest of this long and obviously painfull ride.

GLTA

<< Previous
Bullboard Posts
Next >>